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AbstrAct
Background BRAF V600E mutation defines a specific 
colorectal cancer (CRC) subgroup with poor prognosis. 
Promising preclinical data showed synthetically lethal 
activity of mitotic spindle poisons on BRAF-mutated and 
BRAF-like CRC models. We designed a phase II trial to test 
the activity of vinorelbine in patients with BRAF V600E 
mutated metastatic CRC (mCRC).
Patients and methods Patients progressed to or not 
deemed eligible for standard treatments received oral 
(60 mg/sqm) or intravenous (25 mg/sqm) vinorelbine, 
on days 1 and 8 every 21 days. Primary endpoint was 
objective response rate (ORR).
Results Twenty patients were enrolled; 75% of them were 
highly pretreated. No responses were observed (0%); only 
one patient had a confirmed disease stabilisation (5%). 
Median progression-free survival was 1 month (95% CI 0.8 
to 1.8), median overall survival was 2.1 months (95% CI 
1.6 to 3.7). No serious adverse events were observed.
Conclusions Despite encouraging preclinical data, our 
study did not show signs of clinical activity for vinorelbine 
in this patients’ population. Further investigations on 
molecular heterogeneity and dynamic evolution of BRAF 
V600E mutated mCRC are needed.
bAckground
BRAF V600E mutation is found in about 
8% of metastatic colorectal cancer (mCRC) 
and is an acknowledged marker of poor 
prognosis, defining a disease subgroup with 
specific clinical and pathological character-
istics.1 Targeted dual/triple combinations 
achieved promising results in pretreated 
patients with BRAF-mutated mCRC,2–6 but 
the possibility to obtain a long-term disease 
control seems limited by the rapid emergence 
of acquired resistance.7 8
A specific pattern of BRAF-like gene 
signature has been discovered, thus, deep-
ening the knowledge of disease biology and 
allowing to identify BRAF wild-type tumours 
with a similar aggressive clinical behaviour.9 A 
recent work looked for specific vulnerability 
genes whose suppression could interfere with 
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key question
What is already known about this subject?
 ► Patients with BRAF V600E metastatic  colorectal 
cancer (mCRC) have an awfully poor prognosis and 
derive limited benefit from available treatments.
 ► Combined targeted strategies against murine 
sarcoma viral oncogene homolog B (BRAF), Epidermal 
Growth Factor Receptor  (EGFR) and Mitogen-
activated protein kinase (MEK)/phosphatidylinositol-
3-kinases (PI3K) are under evaluation.
 ► Robust preclinical data highlight the potential 
efficacy of mitotic spindle poisons in this disease 
subtype.
What does this study adds?
 ► Neither a minimal sign of activity was found with 
vinorelbine in a cohort of 20 pretreated patients with 
BRAF V600E mutated mCRC.
 ► No Response Evaluation Criteria in Solid Tumour 
response were reported and only one disease 
stabilisation lasting more than 2 months was 
observed.
 ► No feasibility or safety concerns were evident.
How might this impact on clinical practice?
 ► Vinorelbine should not be recommended as a 
potential option for the treatment of patients with 
mCRC with BRAF V600E mutated tumours, either in 
advanced lines.
 ► Further investigations on molecular heterogeneity 
and dynamic evolution of BRAF V600E mutated 
mCRC are needed.
 ► Moving back to the bench is highly recommended 
before moving to more ambitious and large clinical 
projects.
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Table 1 Patients’ and tumours’ characteristics
Characteristics n=20 N (%)
Sex
  Female 6 (30)
  Male 14 (70)
Age
  Median (range) 64 (28–80)
  ≥70 3 (15)
  <70 17 (85)
Eastern Cooperative Oncology Group 
performance status
  0 11 (55)
  1 9 (45)
Primary tumour location
  Right 13 (65)
  Left 5 (25)
  Extraperitoneal rectum 2 (10)
Primary tumour resected
  Yes 18 (90)
  No 2 (10)
Grading
  G1–G2 13 (65)
  G3–G4 5 (25)
  Gx 2 (10)
Mucinous histology
  Yes 6 (33)
  No 12 (67)
  NA 2
Microsatellite instability (MSI) status
  MSI-H 3 (17)
  Microsatellite stability (MSS)/MSI-L 15 (73)
  Not tested 2
Presentation of metastases
  Synchronous 12 (60)
  Metachronous 8 (40)
Adjuvant chemotherapy
  Fluoropyrimidine+oxaliplatin 5 (25)
  Fluoropyrimidine 1 (5)
  No adjuvant 14 (70)
Number of previous lines of therapy for 
metastatic disease
  0 2 (10)
  1 3 (15)
  2 9 (45)
  ≥3 6 (30)
Number of metastatic sites
  1 2 (10)
Continued
Characteristics n=20 N (%)
  ≥2 18 (90)
Baseline Carcino-Embryonic Antigen
  Normal 5 (29)
  > Upper Limit of Normal (5 ng/mL) 12 (71)
  Not available 3
Table 1 Continued 
cancer progression in BRAF-like models.10 RANBP2 gene 
was deemed responsible for the progression of the mitotic 
spindle, and its suppression caused death in BRAF-like, 
but not in non-BRAF-like cell lines. These findings led to 
test the hypothesis of a potential susceptibility to mitotic 
spindle poisons of CRC models, and vinorelbine (VNR) 
was found the most active drug in BRAF-like models, 
showing no activity in non-BRAF-like ones. In a retro-
spective analysis of a previous study investigating vinca 
alkaloids in patients with mCRC, a BRAF-like gene signa-
ture was found in the only patient achieving a prolonged 
complete response. Drawing from such background, we 
carried out a phase II study aimed at investigating the 




Patients with histologically confirmed mCRC harbouring 
BRAF V600E mutation were eligible if they had 
progressed during or within 3 months from the last 
administration of all standard treatment options (ie, 
fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab, 
aflibercept, regorafenib, cetuximab or panitumumab) or 
were deemed not eligible for such therapies at investiga-
tor’s judgement. Other inclusion criteria were age ≥18 
years, Eastern Cooperative Oncology Group (ECOG) 
Performance Status (PS) 0–1, at least one measurable 
lesion as defined by Response Evaluation Criteria in Solid 
Tumours (RECIST) V.1.1 and adequate hepatic, renal 
and bone marrow function. BRAF V600E mutation was 
detected either on primary tumours or metastatic lesions 
by Pyrosequencing or Sequenom Mass Array, as per local 
laboratory procedure. Mismatch Repair (MMR) status 
was evaluated by immunohistochemistry or multiplex 
PCR. The protocol was approved by local Ethics Commit-
tees at all participating institutions. All patients provided 
written informed consent before study entry.
study design and statistical analysis
This was a multicentre, single-arm, phase 2 trial eval-
uating activity and safety of VNR in patients with BRAF 
V600E mutated mCRC. Enrolled patients received VNR 
orally at a dose of 60 mg/sqm or intravenously at a dose 
of 25 mg/sqm days 1 and 8 every 21 days. Treatment was 
continued until disease progression (PD), unacceptable 
toxicity, death or consent withdrawal.
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Figure 1 Kaplan-Meier curves of the probability of (A) progression-free survival (PFS) and (B) overall survival (OS).
The primary endpoint was objective response rate 
(ORR), defined as the proportion of patients that achieved 
a confirmed complete response or a partial response as 
best response according to RECIST V.1.1. Radiographic 
assessment of tumour response was carried out every 
9 weeks. Secondary endpoints were progression-free 
survival (PFS), defined as the time from treatment start 
to the evidence of PD, or death due to any cause, which-
ever occurred first; overall survival (OS), defined as the 
time from treatment start to the date of death due to 
any cause and safety profile. The Kaplan-Meier method 
was used to estimate PFS and OS durations with 95% 
CI. Adverse events (AEs) were assessed according to 
the National Cancer Institute common toxicity criteria 
(V.4.0).
Considering the usual refractoriness of BRAF V600E 
mutated advanced mCRC to standard treatments, we 
assumed the hypothesis of achieving a 20% ORR with 
VNR monotherapy as acceptable for demonstrating a 
promising clinical activity.
Simon's optimal two-stage design11 was adopted. 
The null hypothesis was set at 5% and tested against a 
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Nausea 3 (15) 0 1 (5) 0
Vomiting 1 (5) 0 1 (5) 0
Diarrhoea 0 3 (15) 1 (5) 0
Gastrointestinal pain 0 2 (10) 0 0
Fatigue 1 (5) 3 (15) 0 0
Anaemia 1 (5) 2 (10) 1 (5) 0
Thrombocytopenia 0 0 0 0
Neutropenia 0 1 (5) 3 (15) 1 (5)
Febrile neutropenia – – 1 (5) 0
one-sided alternative. According to the study design, in 
the first stage, n=21 patients would have been accrued. If 
two or more responses had been observed in the initial 
cohort, the study would have continued to the second 
step, and 20 additional patients would have been accrued 
for a total of 41. The null hypothesis would have been 
rejected in case of five or more responses. This design 
yielded a type I error rate of 0.05 (one sided) and a power 
of 90% for a true response rate of 20%.
results
study population
Between May 2016 and May 2017, a total of 20 patients 
were enrolled at four Italian centres. Baseline patients’ 
and disease characteristics are summarised in table 1. 
The majority of patients were male (70%), aged <70 
years (85%), with ECOG PS 0 (55%). Primary tumours 
were more frequently located in right colon (65%). 
Mucinous histology was reported in 33% of cases and 
MMR deficiency was found in only 17% of cases. Ninety 
per cent of patients had more than one metastatic site 
at the time of enrolment and 75% had received at least 
two lines of systemic treatments. Previous regimens 
included fluoropyrimidines (90%), oxaliplatin (90%), 
irinotecan (80%), bevacizumab (75%), anti-Epidermal 
Growth Factor Receptor (EGFR)s (30%), regorafenib 
(30%) and TAS-102 (15%). Three patients had previ-
ously received BRAF targeted combinations, while one 
patient with a MMR-deficient tumour had been exposed 
to the immune checkpoint inhibitor nivolumab. Two 
patients had not received any treatment before VNR.
Activity and efficacy
No response was observed (ORR 0%). Stable disease was 
reported at the first CT scan reassessment in two (10%) 
patients and confirmed at the second assessment only in 
one case. Thus, the primary endpoint of the study was 
not met and the trial was stopped at the first step, not 
reaching the prespecified number of responses to move 
forward to the second step. At a median follow-up of 
7.4 months, all patients experienced PD and 12 (60%) 
patients died. The median PFS was 1.0 month (95% CI 
0.8 to 1.8) and the median OS was 2.1 months (95% CI 
1.6 to 3.7) (figure 1). Overall, six patients (30%) 
received poststudy therapy: regorafenib in four (20%) 
patients, chemotherapy rechallenge in one patient 
(5%), while one (5%) case with Methyl Guanine Methyl 
Transferase (MGMT) methylation responded to temo-
zolomide.
sAfety
All patients received at least one cycle of treatment and 
were assessed for safety. The median number of cycles 
administered per patient was 2 (range 1–9). Four (9%) 
out of 44 administered cycles were delayed because of 
toxicity. Only one patient required a dose reduction and 
another one early interruption due to toxicity. Treat-
ment-related AEs are summarised in table 2. The most 
frequent grade ≥3 AE was neutropenia that occurred in 
three patients (15%) and became febrile in one case. No 
serious AEs or toxic deaths were reported.
discussion
The identification of efficacious treatment options for 
patients bearing BRAF-mutated tumours is one of the 
most challenging unmet needs in the landscape of mCRC. 
While outcome results with conventional therapies are 
extremely poor and FOLFOXIRI plus bevacizumab is 
regarded by international guidelines as a preferred first-
line choice for these patients,12 targeted approaches 
recently provided encouraging but not outstanding 
results in pretreated patients. Considering the association 
of BRAF mutation with microsatellite instability, immuno-
therapy is emerging as a breakthrough option, but only in 
about one-third of patients.13
Based on the recent preclinical experience by 
Vecchione et al,10 a robust and sound biological rationale 
supported the potential efficacy of VNR and thus encour-
aged the immediate translation of these findings in the 
clinical setting.
Unfortunately, results of our phase II study definitely 
failed to reveal even a minimal signal of activity in 
pretreated BRAF-mutated patients. Different explana-
tions of this discrepancy can be hypothesised.
First, preclinical data suggested a potential activity of 
VNR in cancer cells bearing the BRAF-like signature and 
not in BRAF-mutated cells. However, although the concor-
dance between BRAF mutation and BRAF-like signature 
is not absolute, this gene expression profile is found in 
more than 90% of BRAF-mutated tumours.9 Thus, though 
acknowledging the limited size of our proof-of-concept 
trial, it seems rather unlike that none of our patients actu-
ally harboured the BRAF-like signature.
Second, no data are currently available with regard to 
the dynamic evolution of the BRAF-like signature across 
the time and under the pressure of multiple lines of treat-
ment, so that the choice to mostly include pretreated 
patients might have affected our results.
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Thirdly, BRAF-mutated tumours show a relevant molec-
ular heterogeneity that might translate into clinical 
differences, both in terms of prognosis and sensitivity to 
different agents.14
In conclusion, based on our data, we believe that 
before moving to larger clinical trials investigating the 
potential role of VNR in BRAF-mutated or BRAF-like 
mCRC, a new step back to the bench should be taken 
in order to address these unanswered questions. For 
instance, the adoption of patient-derived xenografts as 
preclinical models might represent a good attempt to 
better mimic the human setting. Based on these findings, 
the BRAF-mutated population could be further dissected 
into different subgroups and a niche of benefit for VNR 
alone or in combination with other synthetically lethal 
agents could be found.
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